BR0207434A - Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos - Google Patents

Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos

Info

Publication number
BR0207434A
BR0207434A BR0207434-6A BR0207434A BR0207434A BR 0207434 A BR0207434 A BR 0207434A BR 0207434 A BR0207434 A BR 0207434A BR 0207434 A BR0207434 A BR 0207434A
Authority
BR
Brazil
Prior art keywords
accelerated
domiciliation
lymphocyte
medicament
agents
Prior art date
Application number
BR0207434-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Marc Bigaud
Volker Brinkmann
Tomasz Sablinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104438A external-priority patent/GB0104438D0/en
Priority claimed from GB0105000A external-priority patent/GB0105000D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0207434A publication Critical patent/BR0207434A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR0207434-6A 2001-02-22 2002-02-21 Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos BR0207434A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104438A GB0104438D0 (en) 2001-02-22 2001-02-22 Organic compounds
GB0105000A GB0105000D0 (en) 2001-02-28 2001-02-28 Organic compounds
PCT/EP2002/001860 WO2002067915A1 (en) 2001-02-22 2002-02-21 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Publications (1)

Publication Number Publication Date
BR0207434A true BR0207434A (pt) 2004-07-06

Family

ID=26245749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207434-6A BR0207434A (pt) 2001-02-22 2002-02-21 Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos

Country Status (11)

Country Link
US (2) US20040087662A1 (enExample)
EP (1) EP1368015B1 (enExample)
JP (1) JP4318921B2 (enExample)
CN (1) CN100479814C (enExample)
AT (1) ATE335475T1 (enExample)
BR (1) BR0207434A (enExample)
CA (1) CA2435739A1 (enExample)
DE (1) DE60213766T2 (enExample)
ES (1) ES2267993T3 (enExample)
PT (1) PT1368015E (enExample)
WO (1) WO2002067915A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
ATE435202T1 (de) 2002-01-11 2009-07-15 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
SI1772145T1 (sl) * 2004-07-16 2011-06-30 Kyorin Seiyaku Kk Postopek za učinkovito uporabo zdravila in postopek za preprečevanje stranskih učinkov
PT2511262T (pt) * 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SG174028A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
SG174029A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928572A (en) * 1971-02-11 1975-12-23 Ayerst Mckenna & Harrison Myriocin and process of preparation
DK0627406T3 (da) * 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
RU2156127C2 (ru) * 1995-12-28 2000-09-20 Еситоми Фармасьютикал Индустриз, Лтд. Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK1319651T3 (da) * 1997-04-04 2005-08-01 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection

Also Published As

Publication number Publication date
CN100479814C (zh) 2009-04-22
HK1060855A1 (en) 2004-08-27
CA2435739A1 (en) 2002-09-06
DE60213766D1 (de) 2006-09-21
DE60213766T2 (de) 2007-08-02
CN1492757A (zh) 2004-04-28
ES2267993T3 (es) 2007-03-16
JP4318921B2 (ja) 2009-08-26
EP1368015B1 (en) 2006-08-09
JP2004527490A (ja) 2004-09-09
US20080015261A1 (en) 2008-01-17
US20040087662A1 (en) 2004-05-06
WO2002067915A1 (en) 2002-09-06
PT1368015E (pt) 2006-12-29
EP1368015A1 (en) 2003-12-10
ATE335475T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
AU2016204344A1 (en) Improved methods and compositions for wound healing
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
CO5221115A1 (es) Nuevos compuestos fungicidas
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ATE281431T1 (de) Resorcin-derivate
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
ATE446776T1 (de) Zusammensetzung zur gefässbeschichtung
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
BR0207434A (pt) Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
TR199901104T2 (xx) Farmas�tik bile�ikler.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
PA8582201A1 (es) Indoles 2,7-sustituidos
ECSP066481A (es) Formulaciones que contienen cobre
WO2006034001A3 (en) Methods of treating hiv infection
WO2004091436A3 (en) Methods and compositions for treating ocular disease
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
ATE391489T1 (de) Haarbehandlungszusammensetzungen
BR0009194A (pt) Composição do resorcinol
AR023644A1 (es) 3-aril-pirazoles substituidos, procedimiento para su obtencion, procedimiento para la lucha contra plantas indeseables, empleo de los mismos contra plantasindeseables y/o como fungicida, y composicion para el tratamiento de plantas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.